The #1 prescribed biologic for Crohn's and UC combined. Quarterly analysis of claims data from October 2023 to September 2024.

For UC and Crohn's patients combined. Quarterly analysis of claims data from October 2023 to September 2024.

For adults with moderate to severe ulcerative colitis (UC) or Crohn's disease

Relief. Remission.
For Real.*

*Long-term remission measured at 52 Weeks. Individual results may vary.

For UC and Crohn's patients combined. Quarterly analysis of claims data from October 2023 to September 2024.

What is ENTYVIO?

ENTYVIO (vedolizumab) is a biologic used to treat Crohn’s disease and ulcerative colitis when certain other medicines haven’t worked well enough or could not be tolerated. Doctors have prescribed ENTYVIO for over 10 years.

With ENTYVIO, there are options

ENTYVIO can be administered 2 different ways, by intravenous (IV) infusion or by a self-administered injection, also known as the ENTYVIO Pen. After at least 2 IV doses, you can use the ENTYVIO Pen at home or on the go.

ENTYVIO (vedolizumab) Pen 108 mg. ENTYVIO (vedolizumab) Pen 108 mg.

Long-term relief and remission

In clinical trials, ENTYVIO helped many patients achieve results at Week 52, both by IV and the ENTYVIO Pen.

Sheila, a real patient.

Real stories from ENTYVIO patients

Everybody’s journey to treatment with ENTYVIO is different. Hear from other people living with Crohn’s and UC share their struggles, their successes, and how ENTYVIO has helped them.

“I was on lots of different medications for about 8 years, up and down, just going from one flare to the next. So I went and talked to my doctor, and he recommended ENTYVIO.”

Sheila, real patient living with Crohn’s

Watch their stories

Supporting you from the start

Cost shouldn’t be a barrier for treatment. Get co-pay support with EntyvioConnect. Plus, get one-on-one nurse support.

Must meet eligibility requirements

Learn about support options
Pay as little as $5. Must meet eligibility requirements.

Must meet eligibility requirements